Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIntercede Regulatory News (IGP)

Share Price Information for Intercede (IGP)

Share Price is delayed by 15 minutes
Get Live Data
115.00    3.50 (3.14%)
Bid:
112.00
Ask:
118.00
Spread: 6.00 (5.357%)
Market Cap: £69.19m
IGP Live PriceLast checked at - London Stock Exchange

Intraday Intercede Share Chart

Trading Update

5 Apr 2017 07:00

RNS Number : 5897B
Intercede Group PLC
05 April 2017
 

 

5 April 2017

INTERCEDE GROUP plc

("Intercede", or the "Group")

Trading Update

 

Intercede announced on 3 March 2017 that the revenue outturn for the financial year ending 31 March 2017 would be approximately £8.0m, with a further £2.0m of new orders in the near term pipeline. The Group today confirms that three of these contract orders were received by the end of the trading period. Subject to the completion of the year end audit, revenues for the year ending 31 March 2017 are expected to be between £8.2 - 8.4m.

The new orders include two customer wins that relate to the deployment of MyID within a US Government Agency and a US Healthcare group. Intercede continues to work diligently to bring the remainder of the near term pipeline into reported revenue. It is confident that this will occur within the first half of the year to 31 March 2018.

The Group is also pleased to report that gross cash balances for the year are £6.9m. This compares to the £6.0m forecast which it highlighted in the earlier statement.

Further detail will be provided within Intercede's final results for the year ending 31 March 2017 which are expected to be published during the week commencing 5 June 2017.

Commenting on the financial close to the year, Richard Parris, Chairman and CEO of Intercede, said;

"After the uncertainty created by the initial phase of the new US Administration, we are pleased that business appears to be returning to normal. Importantly, there is progress in securing the remainder of our near term pipeline and encouraging signs of demand within our core markets. Momentum is building and we view the future with considerable confidence".

Contact

Intercede Group plc

Tel: +44 (0) 1455 558 111

Richard Parris

Chairman & Chief Executive

Andrew Walker

Finance Director

finnCap

Tel: +44 (0) 20 7220 0500

Stuart Andrews

Corporate Finance

Simon Hicks

Corporate Finance

Capital Access Group

Tel: +44 (0) 20 3763 3400

Scott Fulton

Media

Ed Welsby

Investors

About Intercede

Intercede is a software and service company specializing in identity, credential management and secure mobility. Its solutions create a foundation of trust between connected people, devices and apps and combine expertise with innovation to provide world-class cybersecurity. Intercede has been delivering solutions to high profile customers, from the US and UK governments to some of the world's largest corporations, telecommunications providers and information technology firms, for over 20 years. Intercede's product portfolio includes MyID, an identity and credential management system that assigns trusted digital identities to employees citizens and machines. In 2015, Intercede launched MyTAM, enabling trusted applications to be loaded into a mobile device's Trusted Execution Environment (TEE), providing hardware-level security for Android apps. In 2016, Intercede launched RapID, a secure, easy to implement authentication service for mobile apps and cloud services to completely eliminate the need for passwords.

For more information visit: www.intercede.com

 

The information communicated in this announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) No. 596/2014.

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTSSSFMLFWSELL
Date   Source Headline
20th May 20267:00 amRNS-RPartnership with OneSpan
19th May 20267:00 amRNSNotice of Results and Investor Presentation
11th May 20262:50 pmRNSShare Incentive Scheme
21st Apr 20267:00 amRNSNew Contract Upsell Orders and Renewal
9th Apr 20267:00 amRNSTrading Update, Renewals and New Contract Orders
17th Mar 20267:00 amRNSYear End Trading Update
17th Mar 20267:00 amRNSYear End Trading Update
9th Feb 202612:55 pmRNSHolding(s) in Company
15th Jan 202610:44 amRNSExercise of Options & Total Voting Rights
24th Dec 20257:00 amRNSExercise of Options & Total Voting Rights
2nd Dec 20251:05 pmRNSHolding(s) in Company
25th Nov 20257:01 amRNSNew Contract Awards and Renewals
25th Nov 20257:00 amRNSHalf-year Report
22nd Oct 20252:15 pmRNSNotice of Interim Results & Investor Presentation
13th Oct 20257:00 amRNSExercise of Options, PDMR Shareholding & TVR
10th Oct 202510:25 amRNSDirector/PDMR Shareholding
9th Oct 20251:02 pmRNSDirector/PDMR Shareholding
9th Oct 20257:00 amRNSTrading Update, New Contract awards and Renewals
25th Sep 20251:03 pmRNSResult of AGM
22nd Sep 20257:00 amRNSNon-Executive Director Change
22nd Aug 20257:00 amRNSIssue of Equity & Total Voting Rights
12th Aug 20257:00 amRNSNotice of AGM and release of Annual Report 2025
24th Jul 20257:00 amRNS-RFirst CMS to support FIDO enterprise attestation
22nd Jul 20257:00 amRNSGrowth Share Scheme Vesting and Award Allocation
3rd Jul 20257:00 amRNSNew Contract Orders and Renewals
25th Jun 20256:01 pmRNSDirector/PDMR Shareholding
25th Jun 20257:00 amRNSDirector/PDMR Shareholding
24th Jun 20257:00 amRNSFinal Results
22nd May 20253:14 pmRNSNotice of Results & Investor Presentation
7th May 20257:00 amRNSShare Incentive Scheme
1st May 20257:00 amRNS-RIntercede Collaborates with Microsoft and Yubico
8th Apr 20257:00 amRNSTrading Update
2nd Apr 20257:00 amRNSMomentum maintained with New Contract Orders
31st Mar 202511:48 amRNSHolding(s) in Company
12th Mar 20251:54 pmRNSDirector/PDMR Shareholding
12th Mar 20257:00 amRNSContinued Momentum with New Contract Orders
8th Jan 20257:00 amRNSContract Orders and Renewals
24th Dec 20247:00 amRNSTransaction in Own Shares
23rd Dec 20247:00 amRNSTransaction in Own Shares
19th Dec 20247:00 amRNSTransaction in Own Shares
13th Dec 20247:00 amRNSTransaction in Own Shares
11th Dec 20247:00 amRNSTransaction in Own Shares
10th Dec 20247:00 amRNSTransaction in Own Shares
5th Dec 20247:00 amRNSTransaction in Own Shares
2nd Dec 20247:00 amRNSTransaction in Own Shares
29th Nov 20247:00 amRNSTransaction in Own Shares
28th Nov 20247:00 amRNSTransaction in Own Shares
27th Nov 20247:00 amRNSTransaction in Own Shares
26th Nov 20247:00 amRNSHalf-year Report
26th Nov 20247:00 amRNSTransaction in Own Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.